12:00 AM
 | 
Feb 11, 2008
 |  BioCentury  |  Strategy

Amgen's new global view

Amgen Inc. says last week's three-part deal with Takeda Pharmaceutical Co. Ltd.. has little to do with its current restructuring. Instead, Amgen says the deal has more to do with sharing global development expenses.

Takeda received exclusive Japanese rights to 12 biologics being developed in Japan, agreed to acquire Amgen's Amgen K.K. Japanese subsidiary, and became the biotech's worldwide partner for motesanib (AMG 706), an oral agent that inhibits angiogenesis by targeting VEGF receptors 1, 2 and 3; platelet-derived growth factor (PDGF) receptor; and c-kit.

Amgen had been looking for a worldwide partner for motesanib, while Takeda has said it wants to beef up its global business. Motesanib is in Phase II trials as monotherapy in thyroid cancer and in combination with other anti-cancer therapies to treat non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer and other solid tumors.

According to Dominique Monnet, Amgen's VP of global commercial development, Amgen chose Takeda for a number of reasons: "First, its leadership position in Japan makes it a very capable development and commercial partner. It has the scientific expertise and...

Read the full 887 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >